characteristics.text: ERC000011
characteristics.characteristic: ENA-CHECKLIST
characteristics.text: 2022-08-24T00:19:23Z
characteristics.characteristic: ENA-FIRST-PUBLIC
characteristics.text: 2022-08-24T00:19:23Z
characteristics.characteristic: ENA-LAST-UPDATE
characteristics.text: SAMEA110691329
characteristics.characteristic: External Id
characteristics.text: The Peter Doherty Institute for Infection and Immunity, University of Melbourne
characteristics.characteristic: INSDC center name
characteristics.text: 2022-08-24T00:19:23Z
characteristics.characteristic: INSDC first public
characteristics.text: 2022-08-24T00:19:23Z
characteristics.characteristic: INSDC last update
characteristics.text: public
characteristics.characteristic: INSDC status
characteristics.text: ERS12788888
characteristics.characteristic: SRA accession
characteristics.text: E-MTAB-12039:HIV_DN
characteristics.characteristic: Submitter Id
characteristics.text: ArrayExpress
characteristics.characteristic: broker name
characteristics.text: CD4-positive, alpha-beta memory T cell
characteristics.characteristic: cell_type
characteristics.text: receiving suppressive antiretroviral therapy
characteristics.characteristic: clinical history
characteristics.text: human
characteristics.characteristic: common name
characteristics.text: Protocols: We enrolled healthy volunteers and 21 people with HIV (PWH) receiving suppressive antiretroviral therapy (ART) at The Alfred Hospital, Melbourne, Australia (n=11) and University of California San Francisco (UCSF), California, USA (n=10). Participants provided written informed consent before inclusion in the study. As per study protocol inclusion criteria, we enrolled individuals with documented HIV infection aged 18 years or older and receiving combination ART with plasma HIV RNA <50 copies/mL for at least 3 years. We excluded individuals with skin infection at inguinal area; current lower extremity, gastrointestinal or genitourinary infection; chronic venous stasis or lymphedema of lower extremities; blood coagulation disorder or conditions requiring anticoagulant therapy; liver cirrhosis; weight <50 kg or BMI >35; blood pressure >160/100 mmHg or <100/70 mmHg; pregnant or breast feeding; or any with clinically significant cardiac or cerebrovascular disease. Leukapheresis procedures were performed at The Alfred Hospital (n=11) or UCSF (n=10). PD-1+/CTLA4+, PD-1+/CTLA4-, and PD-1-/CTLA4- CD4+ T cells were sorted by flow cytometry into a 10% FCS/PBS buffer. CD4+ T cells were sorted as single-cells using the Chromium 10X Genomics platform. Approximately 10,000 (healthy controls) and 40,000 (HIV patients) CD4+ T cells were loaded per channel onto a Chromium controller (10x Genomics) for generation of gel bead-in-emulsions using 3′ gene expression kits (v3.1; 10x Genomics). Sequencing libraries were prepared using Single Cell 3’ Reagent Kits v3 (10x Genomics) and then converted using the the MGIEasy Universal Library Conversion Kit (BGI).
characteristics.characteristic: description
characteristics.text: human immunodeficiency virus infectious disease
characteristics.characteristic: disease
characteristics.text: PD-1-/CTLA4-
characteristics.characteristic: immunophenotype
characteristics.text: Homo sapiens
characteristics.characteristic: organism
characteristics.text: Homo sapiens
characteristics.characteristic: organism
characteristics.text: blood
characteristics.characteristic: organism part
characteristics.text: Homo sapiens
characteristics.characteristic: scientific_name
characteristics.text: male
characteristics.characteristic: sex
characteristics.text: HIV_DN
characteristics.characteristic: title